Finans, Turkey
Finans, Turkey

Biotie Therapies is a Finnish biotechnology and pharmaceutics company. The company's research and development is focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki. Wikipedia.


Time filter

Source Type

Patent
Biotie Therapies | Date: 2014-02-05

Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-1 antibodies are also given. Pharmaceutical compositions comprising said antibodies and therapeutic uses thereof are also disclosed.


Patent
Biotie Therapies | Date: 2013-08-05

Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance.


Patent
Biotie Therapies | Date: 2011-11-04

Methods are described for inducing cognition and motor function enhancement in patients suffering from Parkinsons disease by administering an effective amount of an Adenosine 2a antagonist. The Adenosine 2a antagonist can optionally be administered in combination with a dopamine precursor, such as levodopa, or a dopamine receptor agonist,


Patent
Biotie Therapies | Date: 2011-11-17

Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance.


Patent
Lundbeck and Biotie Therapies | Date: 2012-04-18

The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dihydrate.


Patent
Biotie Therapies | Date: 2013-12-06

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.


This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.


Patent
Biotie Therapies | Date: 2016-05-02

The invention relates to pyridazinone and pyridone compounds having formula (I) or (I), and pharmaceutically acceptable salts, hydrates, and solvates thereof


Patent
Biotie Therapies and Lundbeck | Date: 2013-06-25

The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dehydrate.


Patent
Biotie Therapies | Date: 2012-03-06

The invention relates to pyridazinone and pyridone compounds having formula (I) or (I), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R_(1)/R_(4 )and X and X_(3 )are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

Loading Biotie Therapies collaborators
Loading Biotie Therapies collaborators